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caused by susceptible Gram-positive bacteria, in- 
cluding methici[[in-resistant S aphylococcus aureus 
(MRSA). Clinical data in pediatric patients is lim- 
ited. 
Methods: A retrospective chart review of pedi- 
atric patients (<18y) who received >2 doses of 
daptomycin between 8/2003 and 11/2006 was per- 
formed. 
Results: Eleven infections [9 Gram-positive bac- 
teremias (GPB) and 2 SSTIs] in 10 patients (7 male, 
3 female) were treated with daptomycin (eight 
received 6 mg/kg/day and three - 4 mg/kg/day). 
Seven patients had hematological malignancies 
(5 ALL, 1 AML, 1 CML) and a[[ were a[[ogeneic 
transplant recipients. Two patients had solid tu- 
mors (neurob[astoma-1 and lung cancer-I). Me- 
dian age was 11 years (range, 2-18). Eight in- 
fections occurred during neutropenia and four 
during corticosteroid therapy. Of the nine bac- 
teremias, a[[ were catheter related (6 CVC, 3 im- 
planted port). Organisms isolated were coagu[ase- 
negative Staphylococcus (CONS): 5; Enterococcus 
J=aecalis: 2, and 2 po[ymicrobia[ infection - CoNS + 
E. mundii, CoNS + Lactobaci[[us. Two infections 
were SSTIs including leg abscess: 1, ce[[u[itis: 1. 
Eleven infections had failed standard antimicrobia[ 
therapy (vancomycin for >4 days in 8 episodes; 
[inezo[id for >3 days in 2 episodes; and quin- 
upristin-da[fopristin - 21 days in 1 episode) 
and had persistently positive blood cultures 
(8 episodes) and/or fever (7 episodes) prior to initi- 
ation of daptomycin. Although susceptible, 4 CoNS 
had vancomycin MlCs of 2.0 ~8/m[ and 3 had MlCs of 
3.0 ~8/m[. The [inezo[id MIC of one E. J=aecalis rose 
from 1.5 to 4.0 ~8/m[ while on daptomycin therapy. 
Median duration of daptomycin therapy was 10 days 
(range, 4-15). Outcomes included clearance of 
blood cultures and defervescence within 72h in 
7 episodes, 1 - grew E. J=aecalis on daptomycin, 
1 - persistently febrile and resolution of both SSTIs. 
No drug related adverse events were documented. 
Conclusion: Daptomycin appears to be a promising 
antimicrobia[ agent for the treatment of GPI in pe- 
diatric cancer patients and merits further clinical 
evaluation. 
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Background: Patients with acute mye[oid leukemia 
(AML) or mye[odysp[astic syndrome (MDS) under- 
going induction chemotherapy are at high risk for 
invasive funga[ infections (IFIs). In a mu[ticenter, 
randomized study of AML/MDS patients, posacona- 
zo[e (POS) prophylaxis prevented significantly more 
breakthrough IFIs than standard azo[e (flucona- 
zo[e [FLU] or itraconazo[e [ITZ]) prophylaxis. 
Objectives: We evaluated mortality rates and 
causes of death in patients from this study who de- 
veloped a breakthrough IFI during POS or standard 
azo[e prophylaxis. 
Methods: Patients with AML or MDS and chemo- 
therapy-induced neutropenia (~<500 ceils/ram 3) 
were randomly assigned to POS oral suspen- 
sion 200m8 tid or oral standard azo[e prophy- 
laxis (FLU suspension 400m8 qd or ITZ solution 
200 m8 bid) with each chemotherapy cycle for ~<12 
weeks. A[[ patients were closely monitored for IFIs 
by current culture, serological, and radiographic 
methods. Primary endpoint was the incidence of 
proven/probable IFIs durin8 the treatment phase 
(from randomization to 7 days after last dose), 
as determined by a blinded expert pane[ using 
EORTC/MSG criteria. Survival information was col- 
lected at 30 days after last dose of study drug or 
100 days after randomization, whichever occurred 
later. Cause of death was investigator-determined. 
Results: 602 patients were enrolled (304 POS; 298 
standard azo[e [240 FLU, 58 ITZ]). Significantly 
fewer IFIs occurred among POS patients (POS, 
7 [2%] vs standard azo[es, 25 [8%]; P=0.0009). 
Aspergi[[osis was the most common IFI in both 
groups, but significantly fewer cases occurred in 
the POS group (POS, 2 [1%] vs standard azo[es, 
20 [7%]; P=0.0001). Overall mortality was n=49 
(16%) and n=67 (22%) for patients in the POS 
and standard azo[e groups, respectively (P = 0.048). 
Of patients who developed a breakthrough IFI, 
1 of 7 (14%) POS patients and 11 of 25 (44%) 
standard azo[e patients died during the study 
(table). The mortality rates for patients with- 
out proven/probable IFIs were 48/297 (16%) and 
56/273 (21%) for POS and FLU/ITZ, respectively. 
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KapLan-Meier analysis of time to death from any 
cause showed significant survival benefit in favor 
of POS (P = 0.035). 
Deaths among patients with probable or proven breakthrough 
IFI during prophylaxis 
Patients with IFI POS (n=7) FLU/ITZ (n =25) 
Total deaths, n (%) 1 (14) 11 (44) 
Cause of death, n (%) 
Progression of IFI 0 8 (32) 
AML/MDS 0 2 (8) 
Intercurrent illness 1 (14) 1 (4) 
Conclusions: In this study, among 32 AML/MDS pa- 
tients with IFIs, mortality rates were high (44% in 
the standard azoLe group and 14% in the POS 
group). An early intervention strategy such as 
POS prophylaxis, which significantly decreases the 
incidence of IFI, may be more effective than wait- 
ing to treat established IFI. 
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Background: The most common disease associa- 
tion of the mould Scopulariopsis is onychomycosis. 
However, in addition, there now exists a smaLL but 
increasing number of reports of invasive infections, 
with high associated mortality, in immunocompro- 
mised patients receiving therapy for malignancies 
or in receipt of bone marrow or solid organ trans- 
plants. 
Objectives: To describe an unusual case of infec- 
tion by Scopulariopsis brevicaulis in a paediatric 
patient with acute [ymphobLastic [eukaemia (ALL) 
and review the Literature on invasive infection 
by Scopulariopsis spp. in immunocompromised pa- 
tients. 
Methods: Case report and Literature review. An- 
tifunga[ MICs were determined at the HPA My- 
cology Reference Laboratory, BristoL, UK. Case: A 
10-year-oLd girl receiving maintenance chemother- 
apy after relapse of ALL foLLowing bone marrow 
transplantation was admitted with fever and a 
dry cough. Her CRP Level was 141 mg/L and her 
absolute neutrophi[ count was 2.1×109/L. BLood 
cultures at this time were negative. ACT  scan 
revealed muLtipLe pulmonary Lesions suggestive of 
funga[ pneumonia. AmBisome was added to em- 
pirical antibiotic therapy. Bronchial [avage was 
not performed. BLood cultures taken 10 days Later 
yielded S. brevicaulis. VoriconazoLe was added 
but blood cultures remained intermittently pos- 
itive. Antifunga[ susceptibility results were then 
received (amphotericin B MIC: 1 mg/L, voricona- 
zoLe: 8 mg/L, itraconazoLe: 16 mg/L, caspofungin: 
4mg/L and terbinafine: 0.5mg/L). The addition 
of oral terbinafine was associated with microbio- 
Logical response and complete resolution of fever. 
AmBisome was Later discontinued and the patient 
discharged. To date, she remains asymptomatic 
and apyrexia[ on oral voriconazoLe and terbinafine. 
However, some pulmonary Lesions remain. 
Results/Conclusions: Review of the Literature in- 
dicates that isolation of Scopulariopsis spp. from 
blood cultures is rare and resistance or reduced 
susceptibility to antifunga[ agents compromises 
therapy of infection. However, in the case pre- 
sented here, blood cultures were positive on 5 oc- 
casions, aLLowing definitive identification and an- 
tifunga[ susceptibility testing, which guided sub- 
sequent therapy. In addition, neutrophi[ counts of 
>1.0×109/L throughout the period of fungaemia 
probably influenced the cLinicaL outcome, which 
was superior to that of the majority of reported 
cases of Scopulariopsis spp. invasive infection in 
immunocompromised patients. 
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Background: Antibiotic-Locks have been shown to 
prevent CVC-reLated bloodstream infection in pts 
with tunneled CVC. An ethanoL-Lock might be a 
good alternative because it has a broad antimi- 
crobia[ spectrum and does not carry the risk of 
selection of antibiotic-resistant microorganisms. 
ObJectives: To evaluate safety and toLerabiLity of 
70% ethanol CVC-Lock. 
Materials & Methods: HematoLogy pts who had 
tunneLLed polyurethane CVC inserted during hos- 
pital stay for chemotherapy were randomized to 
70% ethanol Lock or placebo (NaC[ 0.9%). Lumina 
were Locked for 15rain/day during hospitaLiza- 
tion and 1 ×/week otherwise. EthanoL/pLacebo was 
flushed sLowLy through the CVC afterwards. Liver 
enzymes (g-GT, ASAT) and MCV on cl0 and d14 
were measured and pts were asked to fiLL out a 
questionary on side effects. Recruitment of 440 pts 
is ongoing. This abstract reports on a planned 
